VYNE Sets Merger Close Timing, Finalizing Reverse Split and Dividend
VYNE has more than doubled off its 52-week low of $0.281.
Summary
VYNE Therapeutics provided an update on the anticipated closing timing of its reverse merger with Yarrow Bioscience, alongside the previously announced 1-for-50 reverse stock split and $0.38 per share special cash dividend. The reverse split is set for July 27, with the merger closing expected shortly thereafter. This follows overwhelming stockholder approval on July 18 and the formal dividend and split declaration on July 21. The update signals that the complex transaction is on track, removing a key uncertainty. The merger will transform VYNE into a clinical-stage biotech focused on Yarrow's lead asset YB-101, with a Phase 2a/2b trial in Graves' disease expected to start in Q2 2026.
At the time of this announcement, VYNE was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.7M. The 52-week trading range was $0.28 to $1.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.